Please use this identifier to cite or link to this item:
Title: Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
Authors: Stuckey, Ruth
López-Rodríguez, Juan Francisco
Sánchez Sosa, José Santiago 
Segura Díaz, Adrian 
Sánchez-Farías, Nuria
Bilbao Sieyro, Cristina 
Gómez Casares, María Teresa 
UNESCO Clasification: 32 Ciencias médicas
320101 Oncología
Keywords: BCR-ABL positive
Duration of therapy
Leukemia, et al
Issue Date: 2020
Journal: World Journal of Clinical Oncology 
Abstract: Clinical trials have demonstrated that some patients with chronic myeloid leukemia (CML) treated for several years with tyrosine kinase inhibitors (TKIs) who have maintained a molecular response can successfully discontinue treatment without relapsing. Treatment free remission (TFR) can be reached by approximately 50% of patients who discontinue. Despite having similar levels of deep molecular response and an identical duration of treatment, the factors that influence the successful discontinuation of CML patients remain to be determined. In this review we will explore the factors identified to date that can help predict whether a patient will successfully achieve TFR. We will also discuss the need for the identification of predictive biomarkers associated with a high probability of achieving TFR for the future personalized identification of patients who are suitable for the discontinuation of TKI treatment.
ISSN: 2218-4333
DOI: 10.5306/wjco.v11.i12.996
Source: World Journal of Clinical Oncology [ISSN 2218-4333], v. 11 (12), p. 996-1007 (Diciembre 2020)
Appears in Collections:Artículos
Show full item record

Google ScholarTM




Export metadata

Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.